{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:42:40Z","timestamp":1790804560567,"version":"4.1.0"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Tuberculosis is still a cause of major concern, partly due to the emergence of multidrug-resistant strains. New drugs are therefore needed. Vancomycin can target mycobacteria with cell envelope deficiency. In this study, we used a vancomycin susceptibility assay to detect drugs hampering lipid synthesis in\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mycobacterium bovis<\/jats:named-content>\n            BCG and in\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mycobacterium tuberculosis<\/jats:named-content>\n            . We tested three drugs already used to treat human obesity: tetrahydrolipstatin (THL), simvastatin, and fenofibrate. Only vancomycin and THL were able to synergize on\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. bovis<\/jats:named-content>\n            BCG and on\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. tuberculosis<\/jats:named-content>\n            , although mycobacteria could also be inhibited by simvastatin alone. Lipid analysis allowed us to identify several lipid modifications in\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. tuberculosis<\/jats:named-content>\n            H37Rv treated with those drugs. THL treatment mainly reduced the phthiocerol dimycocerosate (PDIM) content in the mycobacterial cell wall, providing an explanation for the synergy, since PDIM deficiency has been related to vancomycin susceptibility. Proteomic analysis suggested that bacteria treated with THL, in contrast to bacteria treated with simvastatin, tried to recover, inducing, among other reactions, lipid synthesis. The combination of THL and vancomycin should be considered a promising solution in developing new strategies to treat multidrug-resistant tuberculosis.\n          <\/jats:p>","DOI":"10.1128\/aac.00872-16","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T02:53:53Z","timestamp":1470711233000},"page":"6193-6199","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":47,"title":["Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria"],"prefix":"10.1128","volume":"60","author":[{"given":"C\u00e9line","family":"Rens","sequence":"first","affiliation":[{"name":"Universit\u00e9 Libre de Bruxelles (ULB), Unit of Pharmaceutical Microbiology and Hygiene, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Laval","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Structural Biology, University of Toulouse, CNRS, University Paul Sabatier (UMR 5089), Department of Tuberculosis and Infection Biology, Toulouse Cedex 04, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Daff\u00e9","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Structural Biology, University of Toulouse, CNRS, University Paul Sabatier (UMR 5089), Department of Tuberculosis and Infection Biology, Toulouse Cedex 04, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Denis","sequence":"additional","affiliation":[{"name":"Laboratory of Bacteriology, Department of Microbiology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosangela","family":"Frita","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Lille, Universit\u00e9 de Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Baulard","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Lille, Universit\u00e9 de Lille, CNRS, INSERM, CHU Lille, U1019-UMR 8204, Center for Infection and Immunity of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruddy","family":"Wattiez","sequence":"additional","affiliation":[{"name":"Department of Proteomics and Microbiology, University of Mons, Mons, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lef\u00e8vre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Libre de Bruxelles (ULB), Unit of Pharmaceutical Microbiology and Hygiene, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-5462","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Fontaine","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Libre de Bruxelles (ULB), Unit of Pharmaceutical Microbiology and Hygiene, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"WHO report: global tuberculosis control","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. WHO report: global tuberculosis control. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.5588\/pha.14.0087"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00162314"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021154"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2011.01.002"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.179.24.7827-7833.1997"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04856-14"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MGM2-0021-2013"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)52203-1"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(97)86014-4"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.03.007"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2011.01.001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-013-2861-3"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070745"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00530-09"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.150094"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.315473"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004281"},{"key":"e_1_3_3_20_2","first-page":"4","article-title":"Effect of HIV protease inhibitors and orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis","volume":"58","author":"Majumdar A","year":"2011","unstructured":"Majumdar A, Wankhade G, Kamble PD, Harinath BC. 2011. Effect of HIV protease inhibitors and orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis. Indian J Tuberc 58:4\u201310.","journal-title":"Indian J Tuberc"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M113.029942"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00438-004-1088-3"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit550"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku166"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1139\/w04-067"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00175-09"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/0717-6287-47-42"},{"key":"e_1_3_3_28_2","volume-title":"Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard M24-A","author":"National Committee for Clinical Laboratory Standards","year":"2003","unstructured":"National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA."},{"key":"e_1_3_3_29_2","volume-title":"Antibiotics in laboratory medicine","author":"Lorian V","year":"2005","unstructured":"Lorian V. 2005. Antibiotics in laboratory medicine, 5th ed. Lippincott\/Williams & Wilkins, Philadelphia, PA.","edition":"5"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(93)90087-N"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01197-08"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02218-05"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.2.203"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00951-06"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058954"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1003"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.O111.016717"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.581199"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2005.04717.x"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M406796200"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2003.12.005"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00872-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00872-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:09:04Z","timestamp":1645484944000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00872-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1128\/AAC.00872-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00872-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"2016-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}